casein

Casein is a milk protein with multiple roles in a novel drug delivery system that affects postprandial amino acid delivery in different ways through its intragastric coagulation properties.

Casein Kinase II Inhibitor IV is an inducer of epidermal keratinocyte differentiation.

K-Casein (106-116), bovine, is a peptide that impedes platelet aggregation and fibrinogen binding, significantly contributing to the pathophysiology of atherosclerosis [1].

Casein kinase 1δ-IN-9 is a Quinone reductase 2 inhibitor with IC50 of 0.6μM.

Peptone from casein, obtained through the hydrolysis of casein by pancreatic enzymes, is refined to produce a peptone suitable for various applications.

α-Casein (90-95) is a peptide fragment of α-Casein.

Casein Kinase 2 Substrate Peptide, a widely recognized CK2 substrate, is synthesized with its C-terminus conjugated to 5-[(2-aminoethyl)amino]naphthalene-1-sulfonic acid (EDANS). This peptide serves as a tool for determining protein kinase CK2 activity [1].

Casein kinase 1δ-IN-14 (WAY-637081) can be used to study atherosclerosis-related cardiovascular disease.

Casein kinase 1δ-IN-8 is an inhibitor of casein kinase 1δ and is used to treat neurodegenerative diseases such as Alzheimer's disease type.

Casein kinase 1δ-IN-4 (compound 567) is a potent inhibitor of casein kinase 1δ with potential application in Alzheimer's disease research [1].

Casein Kinase inhibitor A86 is a highly effective and orally bioavailable inhibitor of casein kinase 1α (CK1α). Additionally, it displays inhibitory actions towards CDK7 (TFIIH) and CDK9 (P-TEFb). Furthermore, Casein Kinase inhibitor A86 demonstrates the ability to induce apoptosis in leukemia cells, portraying substantial anti-leukemic effects.

Casein Kinase II Substrate, a peptide substrate, is selectively phosphorylated by casein kinase II (CK2) [1].

Casein kinase 1δ-IN-5 is a potent and selective CK-1δ inhibitor, exhibiting an IC50 of 47 nM, and demonstrates neuroprotective and anti-inflammatory effects in vitro, with potential applications in neurodegenerative disease research.

Casein kinase 1δ-IN-1 (WAY-643895) is an inhibitor of casein kinase 1δ (CK1δ), which inhibits CK1δ. Casein kinase 1δ-IN-1 can be used in the study of neurodegenerative diseases such as Alzheimer's disease.

Casein Kinase inhibitor A51 is an orally active casein kinase 1α (CK1α) inhibitor with anticancer activity that induces apoptosis in leukemia cells, and may be used in the study of neck cancers, acute myeloid leukemia, breast and prostate cancers.

Casein kinase 1δ-IN-7 is a Casein kinase 1δ inhibitor for neurodegenerative diseases such as Alzheimer's disease.

Casein kinase 1δ-IN-3 (Casein kinase 1δ-IN-3) (Compound 23a) is a casein kinase 1 delta (CK1d) inhibitor with a pIC50 of 6.5376 M.

Casein kinase 1δ-IN-10 is an inhibitor of casein kinase 1δ (CK1δ).

Casein Kinase II Receptor Peptide, a substrate for casein kinase II, exhibits a Km value of 500 µM. It is utilized to measure the activity of casein kinase II in crude enzyme preparations [1].

Casein Kinase Substrates 3 is a substrate of casein kinase.

Casein kinase 1δ-IN-6 is a potent and selective inhibitor of the protein kinase CK-1δ with an IC50 of 23 nM.Casein kinase 1δ-IN-6 shows neuroprotective and anti-inflammatory activity in both in vitro and in vivo assays.Casein kinase 1δ-IN-6 can be used to study neurodegenerative diseases.

Casein Kinase II Inhibitor IV Hydrochloride is a small-molecule inducer of epidermal keratinocyte differentiation that lead to novel therapeutic approaches for the treatment of skin hyperproliferative disorders.

TBCA (Casein Kinase II Inhibitor III, TBCA) is a highly selective CK2 (casein kinase II) inhibitor, IC50 = 110 nM, Ki = 77 nM. TBCA shows selectivity for CK2 over CK1, DYRK1A and a panel of 27 other kinases.

Sodium caseinates are proteins found in milk that induce proliferation and activation of granulocytes, and can induce granulopoiesis in mice.Sodium caseinates are used as thickeners and emulsifiers and are commonly used in the food industry.

TBB (NSC-231634)(NSC-231634) is a highly selective, ATP/GTP-competitive inhibitor of casein kinase-2 (CK2).

D4476 (Casein Kinase I Inhibitor) is an effective, selective, and cell-permeant CK1 (casein kinase 1) inhibitor( IC50=300 nM in a cell-free assay).

DMAT (Casein kinase II Inhibitor) is a potent and specific inhibitor of CK2(IC50 value of 130 nM).

LY294002 (SF 1101) is a broad-spectrum inhibitor of PI3K, inhibiting PI3Kα, PI3Kδ, and PI3Kβ (IC50=0.5/0.57/0.97 μM). LY294002 is also an inhibitor of DNA-PK (IC50=1.4 μM) and an inhibitor of CK2 (IC50=98 nM). LY294002 activates apoptosis and autophagy.

CK2/ERK8-IN-1 (TMCB) is a dual inhibitor of casein kinase 2 (CK2) (Ki: 0.25 µM) and ERK8 (IC50s: 0.50 μM) with pro-apoptotic efficacy. CK2/ERK8-IN-1 also binds to PIM1, DYRK1A, and HIPK2 (Kis: 8.65 µM, 11.9 µM, and 15.25 µM).

LY-294002 hydrochloride (NSC 697286) is a synthetic molecule inhibitor of PI3Kα/δ/β (IC50: 0.5/0.57/0.97 μM, in cell-free assays); more stable than Wortmannin in solution, and also is a blocker of autophagosome formation.

TAK-715 is a p38 MAPK inhibitor for p38α.

H-89 is a selective inhibitor of cyclic AMP-dependent protein kinase (protein kinase A; IC50: 48 nM). H-89 has weak inhibition on PKG, Casein Kinase, PKC, and other kinases.

Silmitasertib (CX-4945) is a potent, orally bioavailable inhibitor of casein kinase 2 (CK2; Ki: 0.38 nM).

Pepstatin (Pepsin Inhibitor S 735A) is a specific aspartic proteases inhibitor produced by actinomycetes, and inhibits the aspartic proteases cathepsin D, pepsin and renin.

PF-670462 is a potent (IC50 = 7.7 ± 2.2 nM) and selective (>30-fold with respect to 42 additional kinases) inhibitor of CK1ε in isolated enzyme preparations.

Ellagic acid (Gallogen) is a fused four ring compound isolated from the kino of Eucalyptus maculata Hook and E. Hemipholia F. Muell. Activates Factor XII of the blood clotting system which also causes kinin release; used in research and as a dye.

WL47 is a high-affinity ligand for caveolin-1 (CAV1) with a dissociation constant (Kd) of 23 nM, demonstrating potent disruption of CAV1 oligomers. This compound exhibits selectivity for CAV1, with minimal interaction towards BSA, casein, and HEWL. Notably, WL47's molecular structure is 80% smaller than its T20 parent sequence, rendering it a useful tool for investigating caveolin-1 function [1].

CK1-IN-3 is casein kinase 1 (CK1) inhibitor and can be used for research on the treatment or prevention of diseases associated with circadiantiazol rhythm, inflammation diseases.

QLT0267 is an inhibitor targeting integrin-linked kinase (ILK; IC50= 26 nM), showing over 10-fold selectivity against cyclin-dependent kinases 1, 2, and 5 (Cdk1, Cdk2, and Cdk5), and over 1,000-fold selectivity against C-terminal Src kinase (CSK), DNA-PK, Pim-1, Akt, PKC, and casein kinase 2 (CK2) at a concentration of 10 mg/ml. This compound effectively inhibits the proliferation of NPA187 papillary thyroid cancer cells with an IC50 of approximately 3 µM and induces apoptosis in NPA187, DRO, and K4 cancer cell lines. In vivo studies reveal that QLT0267, administered at 100 mg/kg, significantly reduces tumor growth in a DRO mouse xenograft model and diminishes both tumor volume and intratumoral vascularization in a U87MG glioblastoma mouse xenograft model, showcasing its potential for therapeutic applications in cancer treatment.

Peptide B, Bovine, an immunoregulatory peptide derived from αs1-casein B-8P (f1-13) in bovine milk, is predominantly generated during maturation and exhibits antihypertensive effects [1] [2].

alpha-Casozepine is a fragment of alpha(s1)-casein with anxiolytic activity.

Aureusimine B, also known as phevalin, is a natural pyrazinone produced by certain fungi and by Staphylococcus spp., including S. aureus. Its synthesis appears to be initiated by a conserved nonribosomal peptide synthetase that creates a dipeptide (phenylalanine-valine) aldehyde, which then undergoes cyclization and oxidation. Aureusimine B inhibits calpain in a casein hydrolysis assay (IC50 = 1.3 μM), contributes to S. aureus infection in mice, and alters human keratinocyte gene expression.

Ellagic acid (hydrate) is a natural antioxidant and acts as a potent and ATP-competitive CK2 inhibitor (IC50:40 nM, Ki: 20 nM).

Longdaysin is an inhibitor of CK1α and CK1δ (IC50s: 5.6/8.8 µM). It also can inhibit ERK2 (IC50: 52 µM).

BRD4/CK2-IN-1 is the first potent, orally active dual-target inhibitor of BRD4/CK2 (bromodomain-containing protein 4/casein kinase 2), acting on both BRD4 (IC50: 180 nM) and CK2 (IC50: 230 nM). In triple-negative breast cancer (TNBC), BRD4/CK2-IN-1 induces apoptosis and autophagy-related cell death.

CK1-IN-1 (PUN51207) is a casein kinase 1 (CK1) inhibitor. CK1-IN-1 has IC50s of 15 nM, 16 nM, 73 nM for CK1δ, and CK1ε, p38σ MAPK, respectively.

PF-05236216 hydrochloride is a brain penetrant, potent and selective inhibitor of casein kinase 1 delta/epsilon (CK1δ/ε) that modulates circadian rhythms in mice.

High affinity caveolin-1 (CAV1) ligand (Kd = 23 nM); disrupts caveolin-1 oligomers. Exhibits selectivity for CAV1 over BSA, casein and HEWL.

Pyrvinium Iodide is a casein kinase 1α-dependent inhibitor of Wnt/β-Catenin.

TDZD-8 (NP 01139) is an inhibitor of GSK-3β, with an IC50 of 2 μM; minimal inhibitory effect observed on CDK1, casein kinase II, PKA and PKC.